FT218 Leads to Significant Improvement in Narcolepsy Patient

Jennifer Gudeman, PharmD, Vice President of Medical and Clinical Affairs at Avadel Pharmaceuticals, discusses the post hoc analyses of data from the REST-ON clinical trial of FT218, an investigational treatment for narcolepsy
.
Narcolepsy is a rare neurological disorder characterized by excessive sleepiness during the day, often with periods of brief involuntary sleep and/or cataplexy.
As Dr. Gudeman explains, FT218 is a long-acting form of sodium oxybate. A quick-release form of sodium oxybate was FDA approved in 2002 but, due to a short half-life, had to be taken twice a night. With FT218, the long-acting nature allows it to be taken once before bed.
The REST-ON study was a double-blind, randomized, placebo-controlled phase 3 trial assessing the efficacy and safety of FT218 in the treatment of excessive daytime sleepiness and cataplexy in patients suffering from narcolepsy.

[@danielwiseman5958]

How long until this drug is accessible?

[@CP-os1pc]

2023 mid year Hopefully

[@fazpianist]

​@@CP-os1pcSo expensive 😔